Nanoligent, the cancer nanomedicine spin-off developed at UAB and IR Sant Pau, devoted to advancing the protein-based nanomedicines developed at Ulab, has won the Santander X Award in the UAB Emprèn competition. This prestigious recognition highlights our innovative approach to targeting metastatic cancer stem cells using advanced protein nanodrugs. The award reinforces Nanoligent’s position as a leader in next-generation cancer therapeutics and underscores Ulab’s commitment to supporting cutting-edge biomedical innovation.
